Navigation Links
GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
Date:8/11/2008

ATLANTA, Aug. 11 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, biopharmaceutical firm (the Company), developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its financial results and provided an operational update for the six months ended June 30, 2008.

Financial Results for the Three Months and Six Months Ended June 30, 2008

The Company recorded a net loss of $1,284,352 for the three months ended June 30, 2008, compared to $1,333,126 for the same period in 2007. For the six months ended June 30, 2008, the Company's net loss was $1,966,862 as compared to $1,920,407 in 2007. Net losses for 2008 were partially offset by grant revenues of $376,078 and $976,069 for the three month and six month periods, respectively, related to the Company's grant from the National Institutes of Health in support of its HIV/AIDS vaccine development activities. As of June 30, 2008, the Company reported cash balances totaling $3,133,839.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

Management Commentary

Robert McNally, GeoVax's President & CEO, commented, "We are pleased with our six month financial results, including our operational expenses and cash position. Our operational expenses are minimal for a company of our size and stage of clinical trial development. We are particularly pleased with the financing strategy provided by the $10 million common stock purchase agreement with Fusion Capital Fund II, LLC. Funding from the Fusion facility will be utilized for the large Phase 2 preventative AIDS vaccine clinical trial planned to begin this fall and initiation of the therapeutic trial in HIV infected and drug-treated humans."

Dr. McN
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. GeoVax Further Strengthens Management Team
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
4. Genaera Corporation Announces Second Quarter Financial Results
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
7. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
8. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... "Company"), a diversified life sciences company, today announced that ... authorized shares of common stock of the Company from ... held on July 27, 2015 at the Law Offices ... Meeting").   At the Special Meeting, there were 480,655,929 shares ...
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that it has granted to German life sciences ... development and commercialization of biotechnology (collectively, the "Optionee"), ... oral allogenic tumor vaccine technology (the "Technology"), including ... cancer which is ready to enter a Phase ...
(Date:7/27/2015)... FRANKLIN, Tenn. , July 27, ... provider of health care services and one of ... today announced that its parent company and sole ... agreement with Medical Properties Trust, Inc. ("MPT") (NYSE: ... for $900 million in cash.  The transaction is expected to ...
(Date:7/27/2015)... MONTREAL , July 27, 2015   ... that produces sustainable biological accelerators for farmers, has ... Patent and Trademark Office for its patent application ... that accelerate plant growth and enhance yields on ... patent relates to Inocucor,s live IN-M1 microbial consortium ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3
... the Americas -- The Agreement for Europe Will ... of DNA Extraction Kits -- ZyGEM,s Technology Enables ... Automation and High-Throughput Applications -SOLANA BEACH, Calif., and ... Corp. Ltd. and VWR International Europe bvba today ...
... EMERYVILLE, Calif., March 26 Neurobiological Technologies, Inc. (NTI(R)) ... has hired RBC Capital Markets as its exclusive financial ... to enhance shareholder value, including a potential sale of ... Capital Markets to assist us in efficiently determining if ...
... recent study using state-of-the-art genetic testing shows that an all natural skin ... Sirtuin-1, a key anti-aging gene. Until now only Resveratrol, a substance ... to naturally stimulate Sirtuin-1 in humans. Ambra-Lift™ contains no Resveratrol. ... ...
Cached Biology Technology:ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 2ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 3ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 4Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company 2Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 2Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 3Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 4
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... When investigating cancer cells, researchers discovered numerous peculiarities: ... genes are overactive. Do these characteristics have a relation ... inactivate growth brakes or are they just a whim ... scientists perform what are called loss-of-function analyses. They knock ...
... the University of Hawaii Cancer Center and The Queen,s ... from the National Cancer Institute to develop novel methods ... analysis of gene expression and imaging data of the ... a research scientist at the UH Cancer Center, and ...
... An extreme form of pregnancy-related nausea and vomiting known ... of women each year and can lead to hospitalization and ... the only victims. A joint study by ... children whose mothers suffered from HG while carrying them were ...
Cached Biology News:A question of gene silencing 2Hawaii receives funding for liver cancer research 2Extreme morning sickness could lead to lifelong emotional, behavioral disorders in kids 2
... Anti-NY-ESO-1, clone E978 ... : NM_001327 Immunogen ... protein Formulation: mouse ascites ... Quality Assurance: routinely evaluated ...
... to Opsin 1 ( Abpromise for all ... peptide: YEDSTHASIFTYT, corresponding to amino acids 14/26 of ... corresponding to amino acids 18/30 of tiger red ... immunogen. Entrez Gene ID: ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Biology Products: